Sitemap
Pages
Posts
- How ReCor Medical is Taking Action to Confront Racism
- Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement
- ReCor Medical adds another $12m for trial of Paradise renal denervation device
- ReCor Medical Announces 1000th Enrollment and 150th Randomization in RADIANCE-HTN Hypertension Study
- ReCor Medical Announces 6 Month On-Medication Results from RADIANCE-HTN SOLO Clinical Trial and the First Randomization in the RADIANCE-II Pivotal Study
- ReCor Medical Announces Collaboration and Investment with Otsuka Holdings for Asian Commercialization and Clinical Studies in the US and Europe
- ReCor Medical Announces Completion of RADIANCE-HTN SOLO Hypertension Study
- ReCor Medical Announces FDA Approval of IDE for Pivotal Study of Paradise™ Ultrasound Denervation System for Treatment of Hypertension
- ReCor Medical Announces IDE Approval for RADIANCE-HTN Hypertension Clinical Trial
- ReCor Medical Announces Initial Enrollments in the RADIANCE-HTN Hypertension Clinical Trial
- ReCor Medical Announces New Lead Investor and Upcoming Hypertension Trial
- ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise™ Ultrasound Renal Denervation System
- ReCor Medical Announces RADIANCE-HTN SOLO Hypertension Study Meets Primary Efficacy Endpoint, Pivotal Study Submission, and New Principal Investigator
- ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypertension
- ReCor Medical To Release Clinical Trial Results May 23 at EuroPCR in Paris
- ReCor update on the RADIANCE Clinical Program